Management and Treatment of Obesity in Primary Care
An Evolving Landscape
This free CME program from NEJM Group explores the latest evidence on lifestyle, pharmacological, and surgical interventions, as well as recent progress in understanding the causes of obesity. Consisting of four distinct learning opportunities, each activity aims to equip primary care clinicians to navigate the complex, evolving landscape of obesity management.
CME/CE Program Overview
- Examine the roles of environmental and genetic factors in obesity.
- Articulate the mechanisms and pathophysiology of obesity.
- Review common risk factors and comorbidities associated with obesity.
- Assess multiple factors that influence the prevalence of obesity among diverse populations.
- Evaluate the evolving landscape of nutrient-stimulated hormone-based treatment options for obesity, and management of common side effects of these medications for your clinical practice.
- Apply knowledge of current best practices in obesity management to confidently manage patients with obesity.
Disclosure of Support
This activity is supported by an independent educational grant from Lilly and Novo Nordisk.
CME/CE Program Components
Mechanisms, Pathophysiology, and Management of Obesity
(Recommended Starting Point)
On Demand Course
CME Credit: 1 AMA PRA Category 1 Credit™
This seminal NEJM Review Article has been annotated by authors Steven B. Heymsfield, M.D. and Thomas A. Wadden, Ph.D. to include recent advances in the treatment and practice of obesity medicine.
TAKE THIS COURSE AND EARN CMELifestyle Interventions in the Management of Obesity
CME Credit: 1.5 AMA PRA Category 1 Credits™
Through this enduring material, you will gain a comprehensive understanding of how to talk with patients about their weight, how to assess obesity in your patients, and how to incorporate healthy lifestyle changes. Join national obesity experts for a case-based discussion on the latest evidence regarding factors that contribute to weight gain, as well as the data behind dietary interventions. Come away better prepared to speak knowledgeably with your patients, answer their questions, and provide more effective obesity management.
Moderator: Adam H. Gilden, M.D., M.S.C.E.
Speakers: Meghan L. Butryn, Ph.D., and Beverly Tchang, M.D., D.A.B.O.M.
Recent Advancements in the Management of Obesity with a Focus on Pharmacotherapies
CME Credit: 1.5 AMA PRA Category 1 Credits™
Through this enduring material, you will gain a comprehensive understanding of recent advancements in the management of obesity with a focus on pharmacotherapies. Join national obesity experts for a case-based discussion on medications that are approved for chronic weight management. You will understand the mechanism of the new medications that act on gut hormone receptors such as the GLP-1 and GIP receptors, with practical tips on using these in clinical practice. You can also expect a preview of new agents in the pipeline.
Moderator: Adam H. Gilden, M.D., M.S.C.E., D.A.B.O.M.
Speakers: Rebecca M. Andrick, D.O., F.O.M.A., D.A.B.O.M., and Jaime Almandoz, M.D., M.B.A., F.T.O.S., D.A.B.O.M.
Management of Complications of Obesity
CME Credit: 1.5 AMA PRA Category 1 Credits™
Through this enduring material, you will gain a comprehensive understanding of how to assess and manage the complications of obesity. Join national obesity experts for a case-based discussion that includes an overview of old and new approaches to fatty liver disease and tips on optimizing cardiorenal disease in the presence of obesity.
Moderator: Adam H. Gilden, M.D., M.S.C.E.
Speakers: Heather Laskey, M.D., and Chiadi Ericson Ndumele, M.D., Ph.D., M.H.S.
Featured Faculty
Professor and Director, Body Composition-Metabolism Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA
Professor of Psychology in Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Associate Professor of Medicine, University of Colorado School of Medicine, Aurora, CO
Professor and Associate Chair, Department of Psychological and Brain Sciences
Director of Research, Center for Weight, Eating, and Lifestyle Science Drexel University, Philadelphia, PA
Assistant Professor of Clinical Medicine, Weill Cornell Medicine, Comprehensive Weight Control Center, New York, NY
Founder, Weigh to Wellness,
Associate Professor, Rocky Vista University College of Osteopathic Medicine, Denver, CO
Medical Director, Weight Wellness Program
Associate Professor of Medicine, UT Southwestern Medical Center, Dallas, TX
Kaiser Permanente, Denver, CO
Associate Professor of Medicine, Johns Hopkins University, Baltimore, MD
Related Articles
In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 months.
In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo.
Management of obesity in adolescents should routinely include intensive treatment with regard to lifestyle and diet, with antiobesity medications and bariatric surgery considered if indicated.
In this trial, adolescents with obesity assigned to weekly subcutaneous semaglutide plus lifestyle intervention had a greater reduction in BMI than those who received lifestyle intervention alone.
The authors review the many adverse effects of obesity on pregnancy, including hypertension, diabetes, insulin resistance, subfertility, miscarriage, and congenital abnormalities.
In this randomized trial, adults with obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, had major weight loss over 72 weeks.
This trial evaluated the efficacy and safety of time-restricted eating as compared with daily calorie restriction for weight loss at 1 year among patients with obesity. Time-restricted eating did not produce additional benefits with regard to the reduction from baseline in body weight, body fat, and metabolic risk factors as compared with daily calorie restriction.
This double-blind study randomly assigned adults with obesity (or overweight and with one or more weight-related coexisting conditions) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide (2.4 mg) or placebo, plus lifestyle intervention. Semaglutide therapy was associated with sustained, clinically relevant weight reduction.
This study compared long-term mortality and life expectancy among patients who underwent bariatric surgery or received usual obesity care in the Swedish Obese Subjects study and in persons in the SOS reference study. The adjusted median life expectancy with surgery was 3.0 years longer than in control patients but 5.5 years shorter than in the general population.
Evidence is accumulating that eating in a 6-hour period and fasting for 18 hours can trigger a metabolic switch from glucose-based to ketone-based energy, with increased stress resistance, increased longevity, and a decreased incidence of diseases, including cancer and obesity.
The authors report 12-year follow-up results of Roux-en-Y gastric bypass versus no surgery. The results show long-term durability of weight loss and effective remission and prevention of type 2 diabetes, hypertension, and dyslipidemia after Roux-en-Y gastric bypass.
In a study of diet and several exercise modes to reverse frailty and prevent weight-loss–induced reduction in muscle and bone in obese older adults, weight loss plus combined aerobic and resistance exercise was the most effective method of improving functional status.
Obesity is prevalent in the U.S. population and contributes significantly to morbidity and mortality. Treatments include behavioral therapy, pharmacotherapy, and bariatric surgery. Some sequelae of obesity are reversed with weight loss. Maintaining weight loss is a challenge.
Accreditation Information
Accreditation Statement:
The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement:
Annotated Article
The Massachusetts Medical Society designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Live Webinars
The Massachusetts Medical Society designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Materials from Live Webinars
The Massachusetts Medical Society designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statements
All individuals in control of the content for an MMS accredited continuing education activity must disclose all financial relationships with ineligible companies within the past 24-months. The following individuals disclosed relevant relationships with ineligible companies.
Annotated Review Article: Mechanisms, Pathophysiology, and Management of Obesity
Steven B. Heymsfield, M.D.
- Medifast, Abbott, Medical Advisory Board Member
- Versanis, (ended 10/2023) Medical Advisory Board Member
- Novo Nordisk, Data Safety Monitoring Committee
Thomas Wadden, Ph.D.
- Novo Nordisk, WW, Scientific Advisory Board
Webinar: Lifestyle Interventions in the Management of Obesity
Beverly Tchang, M.D., D.A.B.O.M.
- Novo Nordisk, Advisor
Webinar: Recent Advancements in the Management of Obesity with a Focus on Pharmacotherapies
Rebecca M. Andrick, D.O., F.O.M.A., D.A.B.O.M.
- Lilly, Stock
Jaime Almandoz, M.D., M.B.A., F.T.O.S., D.A.B.O.M.
- Novo Nordisk, Advisor
- Eli Lilly and Company, Advisor
- Boehringer Ingelheim, Advisor
Webinar: Management of Complications of Obesity
- N/A
All relevant financial relationships have been mitigated prior to the beginning of each activity in accordance with ACCME and MMS policies. For this activity, all other individuals in control of content did not disclose any relevant financial relationships with ineligible companies.
American Academy of Family Physicians (AAFP)
Annotated Article
The AAFP has reviewed On Demand: Annotated Review Article: Mechanisms, Pathophysiology, and Management of Obesity and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 04/15/2024 to 04/15/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Live Webinars
The AAFP has reviewed Management and Treatment of Obesity in Primary Care: An Evolving Landscape Series, and deemed it acceptable for AAFP credit. Term of approval is from 04/25/2024 to 07/15/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- This session Lifestyle Interventions in the Management of Obesity (4/25/2024) is approved for 1.5 live activity AAFP Prescribed credits.
- This session Recent Advancements in the Management of Obesity with a Focus on Pharmacotherapies (5/23/2024) is approved for 1.5 live activity AAFP Prescribed credits.
- This session Management of Complications of Obesity (6/20/2024) is approved for 1.5 live activity AAFP Prescribed credits.
Enduring Materials from Live Webinars
The AAFP has reviewed Management and Treatment of Obesity in Primary Care: An Evolving Landscape Series — Enduring, and deemed it acceptable for AAFP credit. Term of approval is from 05/15/2024 to 07/15/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- This session Lifestyle Interventions in the Management of Obesity (5/15/2024-5/15/2025) is approved for 1.5 enduring AAFP Prescribed credits.
- This session Recent Advancements in the Management of Obesity with a Focus on Pharmacotherapies (6/15/2024-6/15/2025) is approved for 1.5 enduring AAFP Prescribed credits.
- This session Management of Complications of Obesity (6/27/2024-7/15/2025) is approved for 1.5 enduring AAFP Prescribed credits.
American Academy of Physician Assistants (AAPA)
Management and Treatment of Obesity in Primary Care: An Evolving Landscape: This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 5.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 3/22/2024 to 6/20/2025. AAPA reference number: CME-2011143.
Annotated Article
This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Live Webinars
Each activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Enduring Materials from Live Webinars
Each activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
American Association of Nurse Practitioners (AANP)
Pharmacology Contact Hours
On Demand: Annotated Review Article: Mechanisms, Pathophysiology, and Management of Obesity
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24036571. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Management and Treatment of Obesity in Primary Care: An Evolving Landscape: Live Webinar #1: Lifestyle Interventions in the Management of Obesity
This activity is approved for 1.50 contact hour(s) of continuing education (which includes 0.00 hour[s] of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24036574. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Management and Treatment of Obesity in Primary Care: An Evolving Landscape On-Demand Webinar #1: Lifestyle Interventions in the Management of Obesity, sponsored by Massachusetts Medical Society, is approved for continuing education by the American Association of Nurse Practitioners. Activity ID number 24036577 has been assigned to this application. All sessions are approved as submitted. This activity has been approved for one year (April 30, 2025).
Management and Treatment of Obesity in Primary Care: An Evolving Landscape: Live Webinar #2:
Recent Advancements in the Management of Obesity with a Focus on Pharmacotherapies
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID number 24046609. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Management and Treatment of Obesity in Primary Care: An Evolving Landscape: On-Demand Webinar #2: Recent Advancements in the Management of Obesity with a Focus on Pharmacotherapies
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24046610. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Management and Treatment of Obesity in Primary Care: An Evolving Landscape: Live Webinar #3: Management of Complications of Obesity
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 0.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24056647. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Management and Treatment of Obesity in Primary Care: An Evolving Landscape: On-Demand Webinar #3: Management of Complications of Obesity
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 0.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24056646. This activity was planned in accordance with AANP Accreditation Standards and Policies.